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http://www.jeccr.com/content/33/1/102RESEARCH Open AccessPegylated arginine deiminase synergistically
increases the cytotoxicity of gemcitabine in
human pancreatic cancer
Rouzbeh Daylami1, Diego J Muilenburg1, Subbulakshmi Virudachalam1 and Richard J Bold1,2*Abstract
Background: Pancreatic ductal adenocarcinoma has proven to be one of the most chemo-resistant among all
solid organ malignancies. Several mechanisms of resistance have been described, though few reports of strategies
to overcome this chemo-resistance have been successful in restoring sensitivity to the primary chemotherapy
(gemcitabine) and enter the clinical treatment arena.
Methods: We examined the ability of cellular arginine depletion through treatment with PEG-ADI to alter in vitro
and in vivo cytotoxicity of gemcitabine. The effect on levels of key regulators of gemcitabine efficacy (e.g. RRM2,
hENT1, and dCK) were examined.
Results: Combination of PEG-ADI and gemcitabine substantially increases growth arrest, leading to increased tumor
response in vivo. PEG-ADI is a strong inhibitor of the gemcitabine-induced overexpression of ribonucleotide reductase
subunit M2 (RRM2) levels both in vivo and in vitro, which is associated with gemcitabine resistance. This mechanism is
through the abrogation of the gemcitabine-mediated inhibitory effect on E2F-1 function, a transcriptional repressor
of RRM2.
Conclusion: The ability to alter gemcitabine resistance in a targeted manner by inducing metabolic stress holds great
promise in the treatment of advanced pancreatic cancer.
Keywords: PEG-ADI, Pancreatic cancer, RRM2, GemcitabineBackground
Traditional chemotherapy is cytotoxic to normal and ma-
lignant cells through the induction of apoptosis, however
resistance to apoptotic cell death is a significant barrier to
effective therapy in various cancers. Pancreatic ductal
adenocarcinoma (PDAC) is the prototypical example of a
tumor type resistant to the apoptotic effect of chemother-
apy. Gemcitabine is the mainstay in the chemotherapeutic
treatment of PDAC, though the clinical benefit is a pro-
longation of average survival by a minimal 6 weeks [1].
There has been a great deal of focus on the mechanisms
that confer resistance to apoptosis in pancreatic cancer
including aberrations in central mediators of apoptotic
cell death. This has led to several investigations that* Correspondence: richard.bold@ucdmc.ucdavis.edu
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unless otherwise stated.have combined a variety of therapies directed at targets
that may increase the sensitivity to gemcitabine [2-4]. In
addition, there may be chemotherapy-specific mechanisms
of resistance which can serve as targets for therapy to
restore apoptotic cell death following chemotherapy expos-
ure. Gemcitabine is administered as a pro-drug which must
first be taken up by cells using the transport protein human
equilibrative nucleoside transporter-1 (hENT1) [5]. It is
then converted into an active metabolite by deoxycytidine
kinase (dCK), allowing for incorporation into DNA as a
nucleoside analog but structurally ending DNA synthesis.
Ribonucleotide reductase subunit M2 (RRM2) converts
the active metabolite of gemcitabine into an inactive form.
Alterations of hENT-1, dCK and RRM2 have all been
associated with resistance to gemcitabine-induced cell
death in lung cancer as well as PDAC [6-9]. Therefore,
therapies that specifically target the overexpression of any
of these proteins altering gemcitabine metabolism mayThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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conferring a more significant clinical benefit to patients.
Proof of this approach has been demonstrated by siRNA-
mediated knockdown of RRM2 in colon and pancreatic
cancer in vitro, which restored chemotherapeutic response
to gemcitabine [10-12].
Although regulation of ribonucleotide reductase activity
during cell cycle progression is well understood, the regu-
lation of cellular level of the protein subunits is less well
understood. While it has been frequently observed that
RRM2 is upregulated following exposure to gemcitabine,
the mechanism is unclear though various transcription
factors including AP-1 and NF-κB have been implicated.
RRM2 has been shown to be negatively regulated by the
transcription factor E2F-1 [13,14]. Furthermore, the func-
tion of E2F-1 is regulated indirectly by arginine through
the formation of a activated ternary complex of the argin-
ine methyltransferase, PRMT2, the retinoblastoma (RB)
protein and E2F-1[15]. Arginine also serves as a cellular
store for nitric oxide, which further regulates the function
of RB [16]. Therefore, through two discrete methods of
regulation of RB function, arginine may potentially alter
E2F-1 function and subsequent RRM2 levels. We have
already demonstrated the majority of human PDAC
tumors are deficient for argininosuccinate synthetase
(ASS), the rate-limiting enzyme involved in arginine
synthesis [17]. In this setting of ASS deficiency, PDAC are
dependent on transmembrane amino acid transporters to
maintain intracellular arginine levels. Pegylated arginine
deiminase (PEG-ADI) has shown promise as a targeted
therapeutic agent in the treatment of several types of can-
cer through its ability to decrease extracellular arginine,
which limits the availability for cellular uptake [18-24].
Therefore, given the background potentially linking
arginine metabolism to E2F-1 function, a known regulator
of RRM2 expression, as well as the ability of PEG-ADI
treatment to alter arginine metabolism, we sought to
evaluate the effect of PEG-ADI on the biochemical and
cellular response of PDAC to gemcitabine both in vitro
and in vivo.
Materials and methods
Reagents and cell lines and culture
The pancreatic cancer cell lines MIA-PaCa2 and PANC-1
were purchased from American Type Culture Collection
(Rockville, MD) while the L3.3 cell line was a generous gift
from David McConkey (MDACC, Houston, TX); all cell
lines were cultured in high glucose Dulbecco? s modified
Eagle? s medium (GIBCO) supplemented with 10% fetal
bovine serum, penicillin-streptomycin, sodium pyruvate,
multivitamin and minimal non-essential amino acids
(GIBCO). Pegylated arginine deiminase was generously
provided by DesigneRx (Vallejo, CA) and gemcitabine
was provided by our institutional pharmacy. All otherchemicals were purchased from Sigma-Aldrich, Inc.
unless otherwise stated. We have previously shown that
the L3.3 cell line expresses ASS and that the MIA-
PaCa-2 and PANC-1 cell lines are deficient in ASS [17].
Determination of intracellular amino acid levels
In brief, following PEG-ADI therapy for 24 hours (1.0 μg/
ml), cells are harvested, lysed and cytoplasmic content iso-
lated following centrifugation (15,000 g ? 15 min). Amino
acid levels are quantitated in a 200 μl aliquot using the
Beckman 6300 serum amino acid analyzer, which uses mass
spectrometry to determine individual amino acid preva-
lence. Samples are spiked with AE-cysteine as an internal
standard at a concentration of 3 nM to ensure quantitative
accuracy. To determine the ability of cells to synthesize
arginine, cells were washed and incubated in HBSS for
24 hours and then for an additional four hours in the
absence or presence of citrulline and aspartate, the two
substrates for ASS to synthesize arginine.
MTT assay
96 well plates were seeded with 2.5 ? 10 3 cells per well
and allowed to recover for 24 hours. Following treat-
ment as described in results (eight wells per treatment
group), MTT reagent (5 mg/mL) was added to each well
and the plates incubated (37 C, 4% CO2) in the dark for
4 hours followed by incubation in 10% SDS overnight.
Absorbance at 570 nM (reference filter 655 nM) was
then measured using a microplate spectrophotometer
(BioRad Laboratories). Each treatment was repeated three
times. Statistical differences among treatment groups was
determined by ANOVA with posthoc t-test.
Western blot
Following treatment, cells were harvested with Trypsin
0.05% (GIBCO), washed with PBS and lysed with buffer
(Cell Signaling Technology) containing 20 mM Tris
(pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1% Triton X-100, 2.5 mM sodium pyrophosphate,
1 mM β-Glycerolphosphate, 1 mM Na3VO4, 1 μg/mL
Leupeptin, and 1 mM PMSF. 75 to 100 μg of protein
were loaded and electrophoretically separated by SDS
gel then transferred to nitrocellulose by electrophoresis.
The resulting blots were probed with primary antibodies
and species specific secondary antibodies then developed
by chemilumenscent technique. Antibodies used are as
follows: RRM2, hENT-1, dCK and β-Actin (SantaCruz
Biotechnology), Caspase3 (BD Pharmigen).
Cell cycle analysis
6 well plates were seeded with 1?10 5 cells and after a
24 hour recovery period were treated as described in
results and then harvested with trypsin 0.05%. Cells
were then washed with PBS and incubated in FacsMax
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Prior to analysis, ethanol was removed and cells were
resuspended in RNAse-A (200 μg/mL) at 37?C. After
addition of an equal volume of propidium iodide (200 μg/
mL) and incubation in dark, samples were assayed for PI
content on FACScan flowcytometer (Beckton Dickinson)
and analyzed by FlowJo software (Tree Star, Inc.). The
sub-G1 population was defined as the percentage of cells
with <2 N DNA content. All measurements were repeated
in at least 3 independent experiments.Transfections and reporter assays
Transient transfections were carried out using the Lipo-
fectin Reagent (Life Technologies, Inc., Gaithersburg, MD).
Cells were cultured to 60% confluence in 6 ? 35 mm well
plates. They were serum starved for 24 hours. Cells were
transfected with 2.5 mg of the 3? E2F-tk-luc plasmid
(generous gift from Dr. Hong-Wu Chen, UC Davis) [25].
Transfections were carried out for 12 hours and then the
medium was changed to serum containing medium. After
an additional 12 hours, cells underwent treatment with
either gemcitabine or PEG-ADI, or the combination.
Cells were harvested within 60 hours of transfecton
and lysed per the luciferase reporter protocol (Promega,
Madison WI).Luciferase was assayed on a Monolight
2010 luminometer. Assays were normalized to μg of
total cellular protein quantified using the BioRad reagent,
and expressed as Relative Light Units (RLU) /μg protein.Table 1 Intracellular amino acid concentrations (nmol/100 μl)
and 4 hours later in the absence or presence of exogenous ci
L3.3
Baseline T = 4 hrs (HBSS)
Citrulline N.D. N.D.
Arginine 0.778 0.624
Aspartate 7.565 6.310
Ammonia 1.680 1.105
Lysine 0.567 0.450
Phosphoserine 0.295 0.300
AE-cys (int stand) 3.050 3.218
MIA-PaCa-2
Baseline T = 4 hrs (HBSS)
Citrulline N.D. N.D.
Arginine 0.768 0.949
Aspartate 2.005 2.040
Ammonia 4.316 4.162
Lysine 0.537 0.618
Phosphoserine 0.261 0.219
AE-cys (int stand) 3.188 3.311
Lysine and phosphoserine are shown to demonstrate no other significant differenc
sample at 3 nmoles. N.D. = not detectable.All experiments were performed in triplicate and data
presented as mean +/- standard deviation.
Annexin-V/PI flow cytometry
6 well plates were seeded with 1?10^5 cells and after a
24 hour recovery period were treated as described in
results and then harvested with trypsin 0.05%. After
washing and re-suspending cells in 200uL of PBS, 1 μL
of AnnexinV-Cy5reagent (Biovision Inc.) and 1 μL of PI
(1 mg/mL) were added and cells were incubated in dark
for 15 minutes on ice then immediately analyzed on a
Stratedigm S1400 flow cytometer (Stratedigm Inc.).
Samples were analyzed by drawing quadrants around
the healthy cell population in the negative control sam-
ples using FlowJo software. Apoptotic cells were taken
to be the percentage of Annexin V positive cells. All
measurements were repeated in at least 3 independent
experiments.
Mouse xenograft model
Six to eight-week old athymic mice were maintained in a
dedicated Animal Care Facility according to institutional
guidelines and fed an unrestricted mouse diet during the
entirety of the experiment. Subcutaneous xenografts were
seeded in both flanks of 4 mice per treatment group after
suspending 1?10 6 cells growth medium and diluting 1:1
(v/v) with Matrigel in a final volume of 200 μL. Tumors
were allowed to reach a diameter of approximately 5 mm
prior to initiating treatment. All drugs were diluted in PBSof L3.3 and MIA-PaCa-2 after a 24 hr incubation in HBSS,
trulline and aspartate (1 mM)
T = 4 hrs (+cit/asp) Effect of cit/asp addition
2.375 2.375
6.511 5.887
5.141 −1.169
1.228 .123
0.432 -.018
0.296 −0.004
3.206
T = 4 hrs (+cit/asp) Change
2.513 2.513
0.802 −0.147
1.942 −0.098
4.338 .176
0.572 -.046
0.189 −0.030
3.206
es in amino acid levels, and AE-cys is an internal control spiked into every
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Treatment groups were as follows: control (PBS, 0.5 mL
weekly), ADI (5 IU, weekly), gemcitabine (125 mg/kg,
two days per week) and combination of ADI and gem-
citabine. Tumors were measured twice a week using
calipers and volume was calculated by the following
formula: V = (L ? W)2. Animals were euthanized when
tumors reached a diameter of 15 mm per institutional
guidelines at which time tumors were removed and
weighed. A representative tumor from each group was
then fixed in 10% formalin and another tumor was frozen
in liquid nitrogen. Statistical difference among tumor
weights at sacrifice was determined by the Wilcoxon rank
sum test with post-hoc Student? s t-test.
Immunohistochemistry
Following formalin fixation, tumors were embedded in
paraffin for subsequent immunohistochemistry. Slides were
de-paraffinized and rehydrated through graded alcoholsA
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Figure 1 PEG-ADI depletes extracellular arginine. A) Levels of arginine
cultured in complete media (baseline), following transition to HBSS, or HBS
in tissue culture medium of exponentially growing MIA-PaCa-2 cells (left) a
denoting HPLC peak of arginine.and rinsed with phosphate-buffered saline solution. Antigen
retrieval was performed using the microwave technique
in 10 mmol/L citrate buffer, pH 6. Primary antibodies
included TUNEL SignalStain (K403-50, BioVision Inc.,
Mountain View, CA), and cleaved Caspase-3 (Asp175; Cell
Signaling Technology, Inc., Denvers, MA). Visualization
was performed using a biotinylated, streptavidin-HRP
system (Vector Labs, Inc. Burlingame, CA) followed by
diaminobenzidine. Sections were counterstained with Gill? s
hematoxylin and fixed.
Results
PEG-ADI depletes intracellular arginine stores
We have previously shown that the L3.3 cell line expresses
ASS and the MIA-PaCa-2 cell line is deficient in ASS [17].
To demonstrate that the MIA-PaCa-2 cell line has defi-
cient arginine biosynthesis while this pathway is preserved
in L3.3, cells were transitioned from complete growth
medium to HBSS for 24 hours. Following this period ofL3.3
BSS Plus
Citrulline/Aspartate
Arginine
MIA-PaCa-2 ? PEG-ADI
(nmol/100 μl) in tissue culture media of MIA-PaCa-2 or L3.3 cells when
S supplemented with citrulline and aspartate; B) Levels of amino acids
nd 24 hrs after treatment with PEG-ADI (1 μg/ml) (right) with arrow
Figure 2 (See legend on next page.)
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Figure 2 Interaction of PEG-ADI and gemcitabine. A) Dose-dependent effect of combining gemcitabine with PEG-ADI in MIA-PaCa-2 cells
determined by MTT cytotoxicity assay, B) Effect of PEG-ADI, gemcitabine, or the combination on cell death measured by flow cytometry in
MIA-PaCa-2 (mean of three separate experiments, +/- S.D), C) Effect of PEG-ADI, gemcitabine, or the combination on cell death measured by flow
cytometry in L3.3 with no significant effect of PEG-ADI, either alone or in combination with gemcitabine, D) MIA-PaCa-2 cells treated with
PEG-ADI, gemcitabine or the combination with immunoblotting for caspase 3 following gemcitabine, PEG-ADI or the combination with notation
of cleaved caspase 3, E) Effect of PEG-ADI, gemcitabine or the combination on Annexin V staining of MIA-PaCa-2 cells.
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(the substrates of arginine synthesis by ASS) were added
for a period of four hours. MIA-PaCa-2 was unable to
increase intracellular arginine levels, while L3.3 has a
robust increase in intracellular arginine levels (Table 1,
Figure 1A). We also wished to demonstrate that PEG-
ADI depletes intracellular arginine in the ASS-deficient
MIA-PaCa-2 cell line. Cells were cultured in the absence
or presence of PEG-ADI (1.0 μg/ml) for 24 hours and
intracellular amino acid content determined by HPLC.
Intracellular arginine was undetectable following PEG-
ADI treatment in these cells (Figure 1B).
In vitro interaction of PEG-ADI and gemcitabine
We then sought to evaluate the interaction of PEG-ADI
and gemcitabine on cell death in MIA-PaCa-2 cells, a
human pancreatic cancer cell line relatively resistant to
the cytotoxic effects of gemcitabine but sensitive to the
effects of PEG-ADI [17,26]. A dose-dependent decrease
in cell viability following gemcitabine treatment of MIA-
PaCa-2 cells was observed, with an IC50 of approxi-
mately 500 nM, consistent with other reported studies
(Figure 2A). PEG-ADI also demonstrated a dose-
dependent decrease in cell viability, but when cells were
treated with the combination, there was only a minor
additive effect (Figure 2A). To confirm these findings, flow
cytometry was performed to quantitate the apoptotic frac-
tion of cells following these individual or combined treat-
ments. The combination induced a slightly greater
degree of apoptosis than either treatment alone (Figure 2B).
In the L3.3 cell line, which is ASS-positive/PEG-ADI resist-
ant, no cytotoxicity was observed following PEG-ADI treat-
ment nor did it enhance the effect of gemcitabine
(Figure 2C). To further examine the mode of cell death we
analyzed the effect of combination therapy on markers of
apoptosis. Gemcitabine does not induce strong caspase 3
cleavage when compared to PEG-ADI, and the combin-
ation of the two drugs does not increase caspase 3 cleav-
age beyond PEG-ADI treatment alone in MIA-PaCa-2
(Figure 2D). Because not all apoptosis is caspase
dependent, we examined the effect of combination on
an early marker of apoptosis, the loss of Annexin V posi-
tivity. Consistent with the caspase 3 cleavage findings, the
combination therapy in MIA-PaCa-2 did not induce an
increase in loss of Annexin V positivity (Figure 2E).E2F-1 represses RRM2 levels which is augmented by
gemcitabine treatment
Utilizing the MIA-PaCa-2 cell line, a dose-dependent
increase in RRM2 was seen following gemcitabine expos-
ure (Figure 3A). To evaluate the potential role of E2F-1 in
the regulation of RRM2, siRNA was used to knockdown
protein levels. A dose-finding study demonstrated that 25
nM of E2F-1 siRNA was sufficient to significantly reduce
E2F-1 protein levels (Figure 3B). To demonstrate a func-
tional consequence of E2F-1 knockdown, cells were trans-
fected with a E2F-1 luciferase reporter construct in the
absence or presence of E2F-1 siRNA, which demonstrated
an approximate 80% reduction of E2F-1 transcriptional
activity (Figure 3C). To evaluate the role of E2F-1 in
RRM2 regulation in the setting of gemcitabine exposure,
MIA-PaCa-2 cells were treated with gemcitabine in the
absence or presence of E2F-1 siRNA. Knockdown of E2F-
1 increased RRM2 expression (Figure 3D), consistent with
the known function of E2F-1 as a repressive transcrip-
tional regulator of RRM2 observed in other cell lines.
However, in the setting of E2F-1 knockdown, gemcitabine
treatment did not increase RRM2 levels. Furthermore,
arginine depletion through PEG-ADI treatment both
inhibited RRM2 levels as well as blocked gemcitabine-
mediated upregulation (Figure 3D, right panel). These
data suggest that gemcitabine induces RRM2 expression
by decreasing E2F-1 function, which decreases the inhibi-
tory transcriptional function of E2F-1 on RRM2.
PEG-ADI abrogates gemcitabine-induced up-regulation
of RRM2
To demonstrate that the interaction of gemcitabine and
PEG-ADI on RRM2, which we hypothesized is mediated
by changes in activity of E2F-1, MIA-PaCa-2 cells were
transfected with a E2F-luciferase reporter plasmid [25].
There was a decrease in E2F-1 activity following gemci-
tabine treatment; conversely, PEG-ADI increased E2F-1
activity. Most importantly, the repressive effect of gemcita-
bine on E2F-1 activity was blocked levels by simultaneous
treatment with PEG-ADI (Figure 3E). These data suggest
that PEG-ADI blocks gemcitabine-mediated upregula-
tion of RRM2 through inhibition of the decrease in the
repressive activity of E2F-1 activity following gemcitabine
exposure. We then tested the effect of gemcitabine, PEG-
ADI and the combination on four common mediators of
Figure 3 Regulation of RRM2 by E2F-1. A) Effect of increasing doses of gemcitabine on RRM2 levels in MIA-PaCa-2 cells, B) Effect of E2F-1
siRNA on E2F-1 protein levels in MIA-PaCa-2 cells, C) Effect of E2F-1 siRNA on E2F-1 transcription function in MIA-PaCa-2 cells determined by
E2F-1-driven luciferase expression, D) Effect of E2F-1 siRNA on RRM2 levels following treatment with gemcitabine, PEG-ADI or the combination
compared to the gemcitabine-mediated upregulation of RRM2, E) Effect of gemcitabine, PEG-ADI or the combination on E2F-1 transcription
function in MIA-PaCa-2 cells determined by E2F-1-driven luciferase expression.
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in three different pancreatic cancer cell lines with varying
responsiveness to PEG-ADI. As noted previously, MIA-
PaCa-2 is deficient in ASS expression, and undergoes ar-
ginine depletion following PEG-ADI treatment while
L3.3 expresses ASS and maintains arginine levels fol-
lowing PEG-ADI exposure [17]. Gemcitabine induced sig-
nificant upregulation of RRM2 in MIA-PaCa2 and
PANC-1 cells (another ASS-deficient cell line), but con-
current treatment with PEG-ADI decreased RRM2 levelsto baseline (Figure 4A). Interestingly, PEG-ADI had no
discernible effect on RRM2 levels despite the prior obser-
vation that it could increase E2F-1 function, which we
postulate is an inhibitor of RRM2 transcription. This effect
was not seen in the ASS expressing cell line L3.3, as this
cell line is resistant to any effect of PEG-ADI. When the
effect of these treatments on hENT-1 levels was examined,
only the combination of PEG-ADI and gemcitabine was
noted to decrease hENT-1 levels in the ASS-expressing
L3.3 cell line (Figure 4B). PEG-ADI did not affect the
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Figure 4 PEG-ADI abrogates gemcitabine-mediated upregulation of RRM2 though E2F. A) Effect of PEG-ADI, gemcitabine or the combination
on RRM2 protein levels in MIA-PaCa-2, PANC-1 and L3.3 cells, B) Effect of PEG-ADI, gemcitabine or the combination on hENT-1 protein levels in
MIA-PaCa-2, PANC-1 and L3.3 cells.
Daylami et al. Journal of Experimental & Clinical Cancer Research 2014, 33:102 Page 8 of 12
http://www.jeccr.com/content/33/1/102levels of dCK or CDA expression as a single agent or in
combination with gemcitabine in MIA-PaCa-2, PANC-1
or L3.3 (data not shown).
PEG-ADI synergistically enhances the tumor suppression
effect of gemcitabine in vivo
To test the effect of combination treatment in vivo, mice
bearing subcutaneous xenografts of MIA-PaCa2 were
treated with PBS, PEG-ADI, gemcitabine or the combin-
ation of PEG-ADI and gemcitabine. PEG-ADI demon-
strated little effect on tumor growth, while gemcitabine
showed a modest tumor suppression activity (Figure 5A).
The combination therapy, however, showed remarkable
efficacy without any toxicity to the mice over a period of
7 weeks. Overall growth in the combination group was
approximately 1/3 of that seen in the gemcitabine group
and 1/6 of the PEG-ADI group. At time of animal sacri-
fice the average tumor weight in the combination group
was 0.4 gm versus 1.7 gm in gemcitabine group and 2.7
gm in the PEG-ADI group (Figure 5B).
At time of animal sacrifice tumors were preserved either
by flash freezing in liquid nitrogen or fixed in 10% formalin.
The mode of cell death was examined by immunblotting
tumor lysates for activated caspase 3. No significant
activation of the caspase cascade was observed in any of
the treatments groups, in contrast to the in vitro data
(Figure 5C). The effect of PEG-ADI on gemcitabine
resistance markers dCK and RRM2 was also analyzed by
immunoblotting. As observed in the in vitro studies,
PEG-ADI did not affect dCK expression, but reduced
the induction of RRM2 following gemcitabine treatment
(Figure 5C). These finding were confirmed by immuno-
histochemical analysis of the formalin-fixed, paraffin-
embedded tumors. Gemcitabine treatment significantly
induced RRM2, and this induction was abrogated by
simultaneous PEG-ADI treatment (Figure 6). Further-
more, no significant cytoplasmic cleaved caspase-3 wasobserved in the tumors treated with either PEG-ADI,
gemcitabine or the combination. TUNEL staining also
failed to demonstrate significant differences in apoptosis
among any of the treatment groups. Significant necrosis
was also absent as demonstrated by routine histologic
staining.
Discussion
Despite the clearly cytotoxic effect of gemcitabine in vitro,
clinical experience with its use in the treatment of PDAC
shows only a modest cytostatic effect. In fact, gemcitabine
is approved for palliation of PDAC based on clinical trials
showing superior control of symptoms and only a modest
increase in disease time-to-progression when compared to
5-fluorouracil. One explanation for the failure of gemcita-
bine to show objective tumor response is the high rates
of inducible resistance in PDAC. Multiple pathways of
gemcitabine resistance have been identified in PDAC.
The two best characterized mechanisms of resistance in
PDAC are the downregulation of deoxcytidine kinase
(dCK) and induction of RRM2 [5-9,26,27]. Though PEG-
ADI does not show an effect on expression of dCK, it
shows a significant ability to abrogate the gemcitabine-
mediated induction of RRM2. This effect appears to be
mediated by regulation of E2F-1; gemcitabine suppresses
E2F-1 activity leading to increased RRM2 whereas PEG-
ADI increases E2F-1 function to prevent this potential
mechanism of gemcitabine resistance (Figure 7). This
mechanism is significant because reduction of RRM2 is
not simply a marker of increased chemosensitivity, but a
clinically relevant mechanism to overcome gemcitabine
resistance. Duxbury and colleagues showed that knock-
down of RRM2 by RNA interference significantly enhanced
the cytotoxic effect of gemcitabine [10]. In vivo subcutane-
ous xenografts of MIA-PaCa2 showed significant tumor
suppression when RRM2 siRNA was combined with gemci-
tabine treatment. Therefore, part of the ability of PEG-ADI
Figure 5 PEG-ADI increases the efficacy of gemcitabine in vivo and is associated with abrogation of the gemcitabine-mediated induction
of RRM2. A) Mice with MIA-PaCa-2 xenografts were treated with PBS, PEG-ADI (5 IU, weekly), gemcitabine (125 mg/kg, twice weekly) or combination
of PEG-ADI and gemcitabine. Tumor volumes were measured on indicated days and reported as mean ? SD, B) Weight of MIA-PaCa-2 xenografts
(* = p < 0.05 vs. PEG-ADI; ** = p < 0.05 vs. gemcitabine), C) Lysates of the MIA-PaCa-2 xenografts with immunoblotting for RRM2, dCK or cleaved
caspase 3 following the treatments noted.
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to gemcitabine may be through abrogation of the compen-
satory cellular response of RRM2 induction.
We noted significant conflicts in the in vitro data com-
pared to the in vivo data. In both models, the combination
of gemcitabine and PEG-ADI led to greater anti-tumor ef-
fect though the observed mechanism may be different. In
cell culture experiments, short-term PEG-ADI induced a
caspase-dependent apoptotic cell death. Although the
combination of PEG-ADI with gemcitabine in vivo was
associated with a significant anti-tumor response, very low
levels of caspase cleavage or apoptosis were noted in all
treatment groups. These data would suggest that theprimary mechanism by which PEG-ADI increases the
effect of gemcitabine in vivo is not related to the caspase-
dependent apoptosis that can be observed with higher
doses of PEG-ADI, which we have previously shown can
inhibit pancreatic tumor growth as a monotherapy [17].
Furthermore, PEG-ADI did not have any significant effect
on RRM2 levels in vitro (Figure 4A), though increased
expression of one subunit in vivo (Figure 5C); this mech-
anism may involve regulation of other transcriptional
mediators of RRM2 that are triggered by the local tumor
environment that is not recapitulated in vitro. These dif-
ferences between in vitro and in vivo are an important as-
pect of selection of therapies for combination based on
Figure 6 ImmunohistochemicalstainingofMIA-PaCa-2xenografts. MIA-PaCa-2 tumors treated with PBS (Control), ADI, gemcitabine or the
combination (ADI + Gem) with immunohistochemical staining for RRM2, dCK, activated caspase 3 and TUNEL staining demonstrating the abrogation
of gemcitabine-induced RRM2 with simultaneous ADI treatment. No treatment group had any significant effect on routine histology (H&E), dCK
or cleaved caspase 3 levels or TUNEL staining.
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http://www.jeccr.com/content/33/1/102potential synergy of mechanism for which we propose a
lower dose of PEG-ADI for subsequent human clinical tri-
als than would have been predicted on in vitro data alone.Although PEG-ADI has been developed as a single
agent therapy in hepatocellular carcinoma and melanoma
[21,28,29], this approach may not be optimal for other
RRM2
E2F-1
ASS
Arginine 
RB
PEG-ADI
gemcitabine
PRMT2 
Figure 7 Graphic representation of regulation of RRM2 by
E2F-1. Proposed signaling pathway of regulation of RRM2 by E2F-1
with subsequent upstream inhibition or stimulation by gemcitabine
or arginine.
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has been shown in various models to induce both apop-
totic and autophagic cell death associated with the auxo-
trophic effect of arginine deprivation [30,31], we propose
that targeted arginine deprivation induces cellular changes
that re-program cells allowing sensitization to traditional
chemotherapy [32]. Arginine has diverse intracellular roles
including nitric oxide (NO) formation, protein biosyn-
thesis, and polyamine formation through ornithine gener-
ation. An example of the potentiating effect of arginine
depletion was observed by Tsai et al who demonstrated
that arginine depletion of melanoma cells down-regulated
HIF-1α [33]. This effect was confirmed by Yoon et al in
renal cell carcinoma in which PEG-ADI significantly
reduced tumor angiogenesis and VEGF expression [34]. In
these examples, the effect of arginine deprivation is not
directly cancer cell toxicity, but a secondary effect altering
response to subsequent therapy, such as radiation therapy
[35]. Thus, similar to the experience of angiogenesis inhib-
itors, there have rarely been found to be effects as single
agent therapy though efficacy is observed when combined
with traditional cytotoxic therapies such as radiation or
chemotherapy.
Arginine deprivation in pancreatic cancer cells auxo-
trophic for arginine appears to have multiple effects
though we propose the primary mechanism in the chemo-
sensitizing effect in combination with gemcitabine is
through E2F-1-mediated regulation of RRM2 following
gemcitabine exposure. The combination of PEG-ADI with
gemcitabine in vivo yielded significant anti-tumor effects,
with the benefit potentially involving the RRM2 induced
gemcitabine resistance in PDAC. This implicates arginine
deprivation as the likely mechanism by which PEG-ADI
reduces RRM2 expression.Abbreviations
ASS: Argininosuccinate synthetase; hENT1: Human equilibrative nucleoside
transporter-1; dCK: Deoxycytidine kinase; PDAC: Pancreatic ductal
adenocarcinoma; PEG-ADI: Pegylated arginine deiminase; RB: Retinoblastoma;
RRM2: Ribonucleotide reductase subunit M2.
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